The safety and efficacy of ±3,4-methylenedioxymethamphetamineassisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder

This course page presents an overview of the first completed clinical trial evaluating MDMA as a therapeutic adjunct in psychotherapy for chronic, treatment-resistant posttraumatic stress disorder. The source text describes the study population, treatment structure, outcome measures, and reported safety findings. The study enrolled 20 participants who were randomly assigned to psychotherapy with MDMA or placebo during two 8-hour experimental psychotherapy sessions, alongside preparatory and follow-up non-drug psychotherapy. Outcomes included clinician-rated PTSD symptoms, neurocognitive testing, and physiologic monitoring. The page is most relevant for clinicians, researchers, and mental health professionals interested in psychedelic-assisted therapy, trauma treatment, and clinical trial evidence. It focuses on the published study rather than a skills-based training program.